LIVIVO - Search results -

Search results

Result 1 - 10 of total 61

Search options

Article ; Online: Correction: Differences in treatment of stage I colorectal cancers: a population-based study of colorectal cancers detected within and outside of a screening program.

Toes-Zoutendijk, Esther / Breekveldt, Emilie C H / van der Schee, Lisa / Nagtegaal, Iris D / Elferink, Marloes A G / Lansdorp-Vogelaar, Iris / Moons, Leon M G / van Leerdam, Monique E

Endoscopy

2023

Language	English
Publishing date	2023-11-28
Publishing country	Germany
Document type	Journal Article ; Published Erratum
ZDB-ID	80120-3
ISSN	1438-8812 ; 0013-726X
ISSN (online)	1438-8812
ISSN	0013-726X
DOI	10.1055/a-2217-6054
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 669: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 162: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Cinnabarinic Acid-Induced Stanniocalcin 2 Confers Cytoprotection against Alcohol-Induced Liver Injury.

Joshi, Aditya D / Thinakaran, Gopal / Elferink, Cornelis

The Journal of pharmacology and experimental therapeutics

2022 Volume 381, Issue 1, Page(s) 1–11

Abstract: We recently identified upregulation of a novel aryl hydrocarbon receptor (AhR) target gene, stanniocalcin 2 (STC2), by an endogenous AhR agonist, cinnabarinic acid (CA). STC2 is a disulfide-linked homodimeric secreted glycoprotein that plays a role in ... ...

Abstract	We recently identified upregulation of a novel aryl hydrocarbon receptor (AhR) target gene, stanniocalcin 2 (STC2), by an endogenous AhR agonist, cinnabarinic acid (CA). STC2 is a disulfide-linked homodimeric secreted glycoprotein that plays a role in various physiologic processes, including cell metabolism, inflammation, endoplasmic reticulum (ER) and oxidative stress, calcium regulation, cell proliferation, and apoptosis. Our previous studies have confirmed that CA-induced AhR-dependent STC2 expression was able to confer cytoprotection both in vitro and in vivo in response to injury induced by variety of ER/oxidative insults. Here, we used mouse models of chronic and acute ethanol feeding and demonstrated that upregulation of STC2 by CA was critical for cytoprotection. In STC2 knockout mice (STC2
MeSH term(s)	Animals ; Chemical and Drug Induced Liver Injury, Chronic ; Cytoprotection ; Ethanol/toxicity ; Glycoproteins ; Mice ; Oxazines ; Receptors, Aryl Hydrocarbon/genetics
Chemical Substances	Glycoproteins ; Oxazines ; Receptors, Aryl Hydrocarbon ; Ethanol (3K9958V90M) ; cinnabarinic acid (606-59-7) ; teleocalcin (76687-96-2)
Language	English
Publishing date	2022-01-25
Publishing country	United States
Document type	Journal Article
ZDB-ID	3106-9
ISSN	1521-0103 ; 0022-3565
ISSN (online)	1521-0103
ISSN	0022-3565
DOI	10.1124/jpet.121.000999
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uf I Zs.40: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Differences in treatment of stage I colorectal cancers: a population-based study of colorectal cancers detected within and outside of a screening program.

Toes-Zoutendijk, Esther / Breekveldt, Emilie C H / van der Schee, Lisa / Nagtegaal, Iris D / Elferink, Marloes A G / Lansdorp-Vogelaar, Iris / Moons, Leon M G / van Leerdam, Monique E

Endoscopy

2023 Volume 56, Issue 1, Page(s) 5–13

Abstract: Background: Screen-detected colorectal cancers (CRCs) are often treated less invasively than stage-matched non-screen-detected CRCs, but the reasons for this are not fully understood. This study evaluated the treatment of stage I CRCs detected within ... ...

Abstract	Background: Screen-detected colorectal cancers (CRCs) are often treated less invasively than stage-matched non-screen-detected CRCs, but the reasons for this are not fully understood. This study evaluated the treatment of stage I CRCs detected within and outside of the screening program in the Netherlands. METHODS : Data from the Netherlands Cancer Registry for all stage I CRCs diagnosed between January 1, 2008 and December 31, 2020 were analyzed, comparing patient, tumor, and treatment characteristics of screen-detected and non-screen-detected stage I CRCs. Multivariable logistic regression was used to assess the association between treatment (local excision only vs. surgical oncologic resection) and patient and tumor characteristics, stratified for T stage and tumor location. Results: Screen-detected stage I CRCs were relatively more often T1 than T2 compared with non-screen-detected stage I CRCs (66.9 % vs. 53.3 %;
MeSH term(s)	Humans ; Early Detection of Cancer/methods ; Colorectal Neoplasms/diagnosis ; Colorectal Neoplasms/surgery ; Colorectal Neoplasms/pathology ; Rectal Neoplasms ; Risk Factors ; Colonoscopy
Language	English
Publishing date	2023-11-07
Publishing country	Germany
Document type	Journal Article
ZDB-ID	80120-3
ISSN	1438-8812 ; 0013-726X
ISSN (online)	1438-8812
ISSN	0013-726X
DOI	10.1055/a-2173-5989
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 669: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 162: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Prevalence and predictors of inappropriate prescribing in outpatients with severe mental illness.

Koomen, Lisanne / van de Meent, Ilona / Elferink, Floor / Wilting, Ingeborg / Cahn, Wiepke

Therapeutic advances in psychopharmacology

2023 Volume 13, Page(s) 20451253231211576

Abstract: Background: Potentially inappropriate prescribing (PIP) is frequent in geriatrics and results in an increased risk for adverse effects, morbidity, mortality and reduced quality of life. Research on PIP in psychiatry has mainly focused on elderly ... ...

Abstract	Background: Potentially inappropriate prescribing (PIP) is frequent in geriatrics and results in an increased risk for adverse effects, morbidity, mortality and reduced quality of life. Research on PIP in psychiatry has mainly focused on elderly patients and inpatients. Objectives: To determine the prevalence and the predictors of PIP of psychotropic medication in outpatients with severe mental illness. Design: This study is part of the Muva study, a pragmatic open Stepped Wedge Cluster Randomized Trial of a physical activity intervention for patients (age ⩾ 16 years) with severe mental illness. Methods: A structured medication interview, questionnaires on social functioning, quality of life and psychiatric symptoms, and BMI and waist circumference measurements were performed followed by a structured medication review. Patients were divided into groups: PIP Results: In 75 patients, an average of 5.2 medications of which 2.5 psychotropic medication was used. 35 (46.7%) patients were identified with PIP. Unindicated long-term benzodiazepine use was the most frequently occurring PIP (34.1%). Predictors of PIP were female gender [odds ratio (OR) = 4.88, confidence interval (CI) = 1.16-20.58, Conclusion: The prevalence of PIP of psychotropic medication in outpatients with severe mental illness is high. It is therefore important to identify, and where possible, resolve PIP by frequently performing a medication review with specific attention to females, patients with a higher number of medications and patients with lower social functioning. Trial registration: This trial was registered in The Netherlands Trial Register (NTR) as NTR NL9163 on 20 December 2020 (https://trialsearch.who.int/Trial2.aspx?TrialID=NL9163).
Language	English
Publishing date	2023-11-22
Publishing country	England
Document type	Journal Article
ZDB-ID	2646542-5
ISSN	2045-1261 ; 2045-1253
ISSN (online)	2045-1261
ISSN	2045-1253
DOI	10.1177/20451253231211576
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Correction: Differences in treatment of stage I colorectal cancers: a population-based study of colorectal cancers detected within and outside of a screening program

Toes-Zoutendijk, Esther / Breekveldt, Emilie C. H. / van der Schee, Lisa / Nagtegaal, Iris D. / Elferink, Marloes A. G. / Lansdorp-Vogelaar, Iris / Moons, Leon M. G. / van Leerdam, Monique E.

Endoscopy

2023

Language	English
Publishing date	2023-11-28
Publisher	Georg Thieme Verlag KG
Publishing place	Stuttgart ; New York
Document type	Article
ZDB-ID	80120-3
ISSN	1438-8812 ; 0013-726X
ISSN (online)	1438-8812
ISSN	0013-726X
DOI	10.1055/a-2217-6054
Database	Thieme publisher's database

In stock of ZB MED Cologne/Königswinter

Zs.A 669: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 162: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Identification of factors regulating MET receptor endocytosis by high-throughput siRNA screening.

Gaziova, Ivana / Davey, Robert A / Elferink, Lisa A

Methods in molecular biology (Clifton, N.J.)

2015 Volume 1270, Page(s) 381–394

Abstract: The tyrosine kinase MET, a receptor for hepatocyte growth factor, is a key regulator for normal development and organ renewal via stem cell maintenance. Dysregulated MET signaling contributes to tumor progression and metastasis and is considered a potent ...

Abstract	The tyrosine kinase MET, a receptor for hepatocyte growth factor, is a key regulator for normal development and organ renewal via stem cell maintenance. Dysregulated MET signaling contributes to tumor progression and metastasis and is considered a potent therapeutic target for a growing number of malignancies. Toward that goal it is critical to develop high-throughput assays to identify candidate regulators for the termination of MET signaling. We describe here a rapid and efficient method for identifying cellular factors required for MET ubiquitination, which utilizes high-throughput RNA interference screening (HT-siRNA) with a receptor internalization assay and an In-Cell ELISA in a 96-well format. The assay is amenable to a large array of cell surface proteins as well as genome-wide siRNA libraries, with high signal-to-background ratio and low well-to-well variability.
MeSH term(s)	Carrier Proteins/genetics ; Carrier Proteins/metabolism ; Endocytosis/drug effects ; Gene Expression ; Gene Library ; HeLa Cells ; Hepatocyte Growth Factor/metabolism ; High-Throughput Screening Assays/methods ; Humans ; Ligands ; Protein Binding ; Protein Interaction Mapping/methods ; Proto-Oncogene Proteins c-met/metabolism ; RNA Interference ; RNA, Small Interfering/genetics ; Transfection ; Ubiquitins/genetics ; Ubiquitins/metabolism
Chemical Substances	Carrier Proteins ; Ligands ; RNA, Small Interfering ; Ubiquitins ; Hepatocyte Growth Factor (67256-21-7) ; Proto-Oncogene Proteins c-met (EC 2.7.10.1)
Language	English
Publishing date	2015
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ISSN	1940-6029
ISSN (online)	1940-6029
DOI	10.1007/978-1-4939-2309-0_26
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article ; Online: Receptor-tyrosine-kinase-targeted therapies for head and neck cancer.

Elferink, Lisa A / Resto, Vicente A

Journal of signal transduction

2011 Volume 2011, Page(s) 982879

Abstract: Molecular therapeutics for treating epidermal growth factor receptor-(EGFR-) expressing cancers are a specific method for treating cancers compared to general cell loss with standard cytotoxic therapeutics. However, the finding that resistance to such ... ...

Abstract	Molecular therapeutics for treating epidermal growth factor receptor-(EGFR-) expressing cancers are a specific method for treating cancers compared to general cell loss with standard cytotoxic therapeutics. However, the finding that resistance to such therapy is common in clinical trials now dampens the initial enthusiasm over this targeted treatment. Yet an improved molecular understanding of other receptor tyrosine kinases known to be active in cancer has revealed a rich network of cross-talk between receptor pathways with a key finding of common downstream signaling pathways. Such cross talk may represent a key mechanism for resistance to EGFR-directed therapy. Here we review the interplay between EGFR and Met and the type 1 insulin-like growth factor receptor (IGF-1R) tyrosine kinases, as well as their contribution to anti-EGFR therapeutic resistance in the context of squamous cell cancer of the head and neck, a tumor known to be primarily driven by EGFR-related oncogenic signals.
Language	English
Publishing date	2011-06-07
Publishing country	United States
Document type	Journal Article
ZDB-ID	2582328-0
ISSN	2090-1747 ; 2090-1739
ISSN (online)	2090-1747
ISSN	2090-1739
DOI	10.1155/2011/982879
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Checks and balances: interplay of RTKs and PTPs in cancer progression.

Sastry, Sarita K / Elferink, Lisa A

Biochemical pharmacology

2011 Volume 82, Issue 5, Page(s) 435–440

Abstract: In recent years, targeted therapies for receptor tyrosine kinases (RTKs) have shown initial promise in the clinical setting for the treatment of several tumors driven by these oncogenic signaling pathways. Unfortunately, clinical relapse due to acquired ... ...

Abstract	In recent years, targeted therapies for receptor tyrosine kinases (RTKs) have shown initial promise in the clinical setting for the treatment of several tumors driven by these oncogenic signaling pathways. Unfortunately, clinical relapse due to acquired resistance to these molecular therapeutics is common. An improved understanding of how tumors bypass the inhibitory effects of RTK-targeted therapies has revealed a rich myriad of possible mechanisms for acquired resistance. Protein tyrosine phosphatases (PTPs) can function as oncogenes or tumor suppressors to either enhance or suppress RTK signaling. Recent studies suggest that the loss or gain of function of PTP's can significantly impinge on RTK signaling during tumor progression. Here we review the interplay between RTKs and PTPs as an emerging mechanism for acquired resistance to RTK-targeted therapies, that may aid in the design of improved therapies to prevent and overcome resistance in treatments for cancer patients.
MeSH term(s)	Animals ; Disease Progression ; Drug Resistance, Neoplasm ; Humans ; Neoplasms/enzymology ; Neoplasms/etiology ; Protein Tyrosine Phosphatase, Non-Receptor Type 1/physiology ; Protein Tyrosine Phosphatase, Non-Receptor Type 11/physiology ; Protein Tyrosine Phosphatases/physiology ; Receptor Protein-Tyrosine Kinases/antagonists & inhibitors ; Receptor Protein-Tyrosine Kinases/physiology ; Tumor Suppressor Proteins/physiology
Chemical Substances	Tumor Suppressor Proteins ; Receptor Protein-Tyrosine Kinases (EC 2.7.10.1) ; PTPN1 protein, human (EC 3.1.3.48) ; Protein Tyrosine Phosphatase, Non-Receptor Type 1 (EC 3.1.3.48) ; Protein Tyrosine Phosphatase, Non-Receptor Type 11 (EC 3.1.3.48) ; Protein Tyrosine Phosphatases (EC 3.1.3.48)
Language	English
Publishing date	2011-09-01
Publishing country	England
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Review
ZDB-ID	208787-x
ISSN	1873-2968 ; 0006-2952
ISSN (online)	1873-2968
ISSN	0006-2952
DOI	10.1016/j.bcp.2011.06.016
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 19: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Differences in treatment of stage I colorectal cancers: a population-based study of colorectal cancers detected within and outside of a screening program

Toes-Zoutendijk, Esther / Breekveldt, Emilie C. H. / van der Schee, Lisa / Nagtegaal, Iris D. / Elferink, Marloes A. G. / Lansdorp-Vogelaar, Iris / Moons, Leon M. G. / van Leerdam, Monique E.

Endoscopy

2023 Volume 56, Issue 01, Page(s) 5–13

Abstract	Background: Screen-detected colorectal cancers (CRCs) are often treated less invasively than stage-matched non-screen-detected CRCs, but the reasons for this are not fully understood. This study evaluated the treatment of stage I CRCs detected within and outside of the screening program in the Netherlands. Methods : Data from the Netherlands Cancer Registry for all stage I CRCs diagnosed between January 1, 2008 and December 31, 2020 were analyzed, comparing patient, tumor, and treatment characteristics of screen-detected and non-screen-detected stage I CRCs. Multivariable logistic regression was used to assess the association between treatment (local excision only vs. surgical oncologic resection) and patient and tumor characteristics, stratified for T stage and tumor location. Results: Screen-detected stage I CRCs were relatively more often T1 than T2 compared with non-screen-detected stage I CRCs (66.9 % vs. 53.3 %; P < 0.001). When only T1 tumors were considered, both screen-detected colon and rectal cancers were more often treated with local excision only than non-screen-detected T1 cancers (odds ratio [OR] 2.19, 95 %CI 1.93–2.49; and OR 1.29, 95 %CI 1.05–1.59, respectively), adjusted for sex, tumor location, lymphovascular invasion (LVI) status, and tumor differentiation. Conclusions : Less invasive treatment of screen-detected stage I CRC is partly explained by the higher rate of T1 cancers compared with non-screen-detected stage I CRCs. T1 stage I screen-detected CRCs were also more likely to undergo less invasive treatment than non-screen-detected CRCs, adjusted for risk factors such as LVI and tumor differentiation. Future research should investigate whether the choice of local excision was related to unidentified cancer-related factors or the expertise of the endoscopists.
Language	English
Publishing date	2023-11-07
Publisher	Georg Thieme Verlag KG
Publishing place	Stuttgart ; New York
Document type	Article
ZDB-ID	80120-3
ISSN	1438-8812 ; 0013-726X
ISSN (online)	1438-8812
ISSN	0013-726X
DOI	10.1055/a-2173-5989
Database	Thieme publisher's database

In stock of ZB MED Cologne/Königswinter

Zs.A 669: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 162: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Serotonin 5-HT

Land, Michelle A / Chapman, Holly L / Davis-Reyes, Brionna D / Felsing, Daniel E / Allen, John A / Moeller, F Gerard / Elferink, Lisa A / Cunningham, Kathryn A / Anastasio, Noelle C

Scientific reports

2019 Volume 9, Issue 1, Page(s) 16737

Abstract: A non-synonymous single nucleotide polymorphism of the human serotonin 5- ... ...

Abstract	A non-synonymous single nucleotide polymorphism of the human serotonin 5-HT
MeSH term(s)	Calcium/metabolism ; Cell Membrane/drug effects ; Cell Membrane/metabolism ; Cysteine/chemistry ; Cysteine/genetics ; Humans ; In Vitro Techniques ; Polymorphism, Single Nucleotide ; Receptor, Serotonin, 5-HT2C/chemistry ; Receptor, Serotonin, 5-HT2C/genetics ; Receptor, Serotonin, 5-HT2C/metabolism ; Serine/chemistry ; Serine/genetics ; Serotonin/pharmacology ; Serotonin Receptor Agonists/pharmacology
Chemical Substances	Receptor, Serotonin, 5-HT2C ; Serotonin Receptor Agonists ; Serotonin (333DO1RDJY) ; Serine (452VLY9402) ; Cysteine (K848JZ4886) ; Calcium (SY7Q814VUP)
Language	English
Publishing date	2019-11-13
Publishing country	England
Document type	Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	2615211-3
ISSN	2045-2322 ; 2045-2322
ISSN (online)	2045-2322
ISSN	2045-2322
DOI	10.1038/s41598-019-53124-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito